Drug Type Biosimilar, Monoclonal antibody |
Synonyms- |
Target |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization AYUMI Pharmaceutical Corp.Startup |
Active Organization AYUMI Pharmaceutical Corp.Startup |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (27 Sep 2017), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Colitis, Ulcerative | JP | AYUMI Pharmaceutical Corp.Startup | 27 Sep 2017 |
Crohn Disease | JP | AYUMI Pharmaceutical Corp.Startup | 27 Sep 2017 |
Erythrodermic psoriasis | JP | AYUMI Pharmaceutical Corp.Startup | 27 Sep 2017 |
Psoriasis vulgaris | JP | AYUMI Pharmaceutical Corp.Startup | 27 Sep 2017 |
Pustular psoriasis | JP | AYUMI Pharmaceutical Corp.Startup | 27 Sep 2017 |
Rheumatoid Arthritis | JP | AYUMI Pharmaceutical Corp.Startup | 27 Sep 2017 |